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Background. Infections with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) are emerging
worldwide. We investigated an outbreak of severe CA-MRSA infections in children following out-patient vaccination. Methods
and Findings. We carried out a field investigation after adverse events following immunization (AEFI) were reported. We
reviewed the clinical data from all cases. S. aureus recovered from skin infections and from nasal and throat swabs were
analyzed by pulse-field gel electrophoresis, multi locus sequence typing, PCR and microarray. In May 2006, nine children
presented with AEFI, ranging from fatal toxic shock syndrome, necrotizing soft tissue infection, purulent abscesses, to fever
with rash. All had received a vaccination injection in different health centres in one District of Ho Chi Minh City. Eight children
had been vaccinated by the same health care worker (HCW). Deficiencies in vaccine quality, storage practices, or preparation
and delivery were not found. Infection control practices were insufficient. CA-MRSA was cultured in four children and from
nasal and throat swabs from the HCW. Strains from children and HCW were indistinguishable. All carried the Panton-Valentine
leukocidine (PVL), the staphylococcal enterotoxin B gene, the gene complex for staphylococcal-cassette-chromosome mec type
V, and were sequence type 59. Strain HCM3A is epidemiologically unrelated to a strain of ST59 prevalent in the USA, although
they belong to the same lineage. Conclusions. We describe an outbreak of infections with CA-MRSA in children, transmitted
by an asymptomatic colonized HCW during immunization injection. Consistent adherence to injection practice guidelines is
needed to prevent CA-MRSA transmission in both in- and outpatient settings.
Citation: Chi Thuong T, Dac Tho N, Thi Hoa N, Minh Phuong NT, Van Tuan L, et al (2007) An Outbreak of Severe Infections with Community-Acquired
MRSA Carrying the Panton-Valentine Leukocidin Following Vaccination. PLoS ONE 2(9): e822. doi:10.1371/journal.pone.0000822
INTRODUCTION
Staphylococcus aureus is a commensal of the anterior nares in 25% of
the human population, and carriage is a risk factor for infection
and transmission of S. aureus in hospitals and the community [1,2].
While methicillin resistant S. aureus (MRSA) are widespread in
hospitals, community-acquired MRSA (CA-MRSA) is increasingly
responsible for severe skin and soft tissue infections, necrotising
fasciitis, and a fatal form of necrotising pneumonia, in previously
healthy individuals [3–5]. Currently, CA-MRSA are responsible
for 15–74% of skin and soft-tissue infections among patients
presenting to emergency departments in the USA [6].
CA-MRSA are often from unique S. aureus lineages, and carry
additional or variant virulence and resistance genes on mobile
genetic elements (MGE). The toxin Panton-Valentine leukocidin
(PV-luk) and a small variant of the methicillin-resistance cassette
(SCCmec types IVa, IVc and V), encoding methicillin-resistance but
not multi-drug resistance, are typical. CA-MRSA have evolved
independently from MRSA found in hospitals. Analysis of 117 CA-
MRSAisolatesfromthreecontinentssuggeststhespreadofalimited
number of clones, which are associated with a particular geographic
origin but may have originated from methicillin-sensitive S. aureus
clones which are prevalent on different continents [7,8].
Infections with CA-MRSA typically occur in clusters in settings
with multiple and prolonged close contacts between individuals,
such as families, schools, hospital nurseries and sport teams, or in
situations were hygiene is poor, such as in jails and facilities for
homeless persons [2,9–13]. Here we report an outbreak of severe
infections with CA-MRSA, including one with a fatal outcome,
occurring within two weeks among nine children in Ho Chi Minh
City (HCMC), Viet Nam in May 2006. The epidemiological and
microbiological investigations indicate these infections were due to
transmission of CA-MRSA by a single health care worker during
routine vaccination practice.
METHODS
Epidemiological and clinical investigations
A field epidemiological investigation was initiated following reports
of an outbreak of serious adverse events following immunization
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PLoS ONE | www.plosone.org 1 September 2007 | Issue 9 | e822(AEFI), involving six children who were admitted to the Pediatric
Hospital Number One between 8 and 10 May 2006. Potential
cases of AEFI were searched using the vaccination records of the
community health centres. Face-to-face interviews with the
parent/guardian of affected children and hospital and community
health centre staff were completed. A review of vaccination
settings and procedures was carried out through a series of visits to
vaccination sites, review of records and interviews with vaccination
staff and supervisors. Clinical data were obtained by review of the
medical records of all cases. This outbreak investigation was
initiated and approved by the Health Service of Ho Chi Minh
City. Parents or guardians and health care workers and their
family members gave informed verbal consent before entry in the
investigation.
Microbiological investigations
Pus was collected from abscesses by needle puncture or from
necrotic material using a sterile swab, and cultured using standard
culture methods. Blood cultures were performed on admission
before administration of antimicrobial therapy, using the BAC-
TEC 9050 continuous monitoring blood culture instrument
(BectonDickinson, NJ, USA). Cerebrospinal fluid cultures were
not performed.
Screening for carriage of MRSA was performed on 19 May
2006, after clinical samples became positive with MRSA. Trained
laboratory staff collected cotton swab samples (Transwab, MW&E,
Corsham, UK) from anterior nares, throat and perineum of two
vaccinators (vaccinators X and O), two examining medical officers
and the person responsible for vaccine storage, all of whom were
directly involved in the handling or administration of vaccines. In
addition, the mothers of three children (Child 2, 4 and 9 in
Table 1) were screened on the same day. Vaccinator X and all her
household members (husband, daughter, son) were screened for
MRSA carriage on 23 June 2006. Vaccinator X was screened
again on 7 September 2006. Swab samples were inoculated onto
sheep blood agar (BA), mannitol salt agar containing oxacillin
(2 mg/l) (OMSA) and placed in Mueller Hinton broth, within one
hour after collection. Plates were incubated for 24–48 hours at
35uC and the broth was incubated for 24 hours and subcultured
onto BA and OMSA.
S. aureus was identified using catalase, slide coagulation and
DNAse tests. Susceptibilities to eight antimicrobial agents
(oxacillin, erythromycin, clindamycin, rifampin, ciprofloxacin,
trimethoprim-sulfamethoxazole, gentamicin and vancomycin)
were tested by disk diffusion test according to CLSI standards
[14]. MIC for oxacillin was determined using E-test (AB-Biodisk,
Solna, Sweden) on Mueller Hinton agar without NaCl.
Molecular genotyping was performed by pulse field gel
electrophoresis (PFGE) with SmaI digestion [15]. Genetic re-
latedness was assessed using the criteria established by Tenover
et al. [16]. Multi locus sequence typing (MLST) was performed as
described by Enright et al. [17]. Sequence type (ST) assignment
was based on the sequence of the alleles at each locus of seven
housekeeping genes included in the MLST scheme, using the
MLST database (www.mlst.net). MLST results were analyzed
using the program eBURST (http://eburst.mlst.net) on the entire
MLST database, to assign the ST to its clonal complex [18].
Characterization of the staphylococcal cassette chromosome mec
elements (SCCmec) was performed by PCR using the primers as
described by Chongtrakool [19]. The presence of 22 specific
staphylococcal virulence genes was determined by PCR [20].
Amplicons were sequenced to confirm the identity of the PCR
products.
A recently developed microarray, containing PCR products
representing every predicted open reading frame present in seven
whole-genome sequences of S. aureus (strains MRSA 252, N315,
Mu50, COL, 8325, MW2, MSSA476) was used for further
analysis [21]. DNA of strains HCM3A and HT2001-0751 was
extracted using a genomic DNA extraction kit (EdgeBioSystems,
Gaithersburg, MD, USA), labeled and hybridised to the array, and
data were analyzed as described previously [21]. Strain HT2001-
0751 (SCCmec IV-MRSA-ST59), was provided by Dr. J. Etienne,
Lyon, France.
RESULTS
The outbreak investigation led to the discovery of three additional
children bringing the total to nine children, who required
hospitalization for AEFI. All children were previously healthy
and had been immunized in one of five different Health Centres in
the same District between 28 April and 10 May 2006. Clinical and
laboratory data on admission, and outcome of all children with
AEFI are presented in Table 1. Three children presented with
a rapidly progressive illness requiring respiratory and circulatory
support, one of whom died and one of whom suffered severe
neurological sequelae. Signs and symptoms in these children
included high fever, regional or generalized rash or severe
erythema, extensive and rapidly expanding swelling at the
injection site, and shock, with raised creatine phosphokinase,
serum creatinine, AST and ALT levels, all of which are
compatible with toxic shock syndrome (TSS). Four children
presented with skin and soft tissue infections, including one child
(Child 4 in Table 1) with severe tissue necrosis requiring extensive
surgical debridement which suggested the presence of necrotizing
fasciitis (Figure 1). All skin and soft tissue infections developed at
the vaccine injection site. Three children were admitted with an
unspecific and relatively mild general illness (Table 1).
Six of the nine children received MMR vaccine in a single-dose
lyophilized formulation with a single-dose diluent, two children
received vaccinations of a two-dose liquid formulation of Hepatitis
B vaccine, and the remaining child received a single dose
lyophilized varicella vaccine. One of two nurses (vaccinator X or
O) conducted the immunizations. All children with AEFI, except
Child 9, were vaccinated by vaccinator X, who vaccinated a total
of 185 children between 28 April and 10 May 2006, while
vaccinator O vaccinated 39 children.
The investigation did not find any deficiencies or breaks in
vaccine storage practices. Vaccines were prepared and, in the case
of lyophilized vaccines, reconstituted immediately prior to
administration, and delivered using single-use sterile syringe and
needle. The injection site was swabbed with 70% isopropyl alcohol
before injection. Infection control practices were found to be
inadequate, including lack of hand washing facilities in at least one
vaccination room visited. Vaccinator X indicated she routinely
wore a single glove during vaccine reconstitution and administra-
tion, while vaccinator O used two gloves. Both vaccinators only
changed their gloves after immunizing approximately three to six
children and did not wash or disinfect their hands between
children. Vaccinator X reported symptoms of a common cold in
the days prior to 9 May 2006. She did not report any skin lesions
and did not have skin lesions on inspection on 19 May 2006.
MRSA was isolated from pus from injection site abscesses in
four children while blood cultures remained negative for all
children. MRSA was also isolated from nose and throat swab
samples from vaccinator X. Swab samples from mothers of
Children 2, 4, and 9 were negative.
All five MRSA isolates from four children and vaccinator X
were resistant to oxacillin (MIC 2–4 mg/l), erythromycin and
CA-MRSA after Vaccination
PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e822clindamycin but sensitive to all other drugs tested. The presence of
the mecA gene was confirmed in all isolates. All five isolates had
identical band patterns on PFGE analysis (Figure 2) and contained
SCCmec cassettes type V (or type 5C). All strains were ST59 by
MLST. PCR detected the presence of PV-lukSF and seb. On repeat
testing on 23 June 2006, vaccinator X still carried the same strain
of MRSA in here nose and throat (Figure 2) and her son also
carried MRSA in his nose. Sensitivity patterns of the strains of
vaccinator X and son were identical, but they had few bands in
common on PFGE. The son’s strain was PV-lukSF negative,
SSCmec type IVa and a one allele variant of ST45, indicating that
the isolates from vaccinator X and her son were unrelated. Further
repeat nose and throat cultures from vaccinator X were collected
on 7 September 2006 and were MRSA negative. Due to the
Table 1. Clinical characteristics and laboratory values of children on admission, and outcome
..................................................................................................................................................
Variable* Child 1 Child 2 Child 3 Child 4 Child 5 Child 6 Child 7 Child 8 Child 9
Age (months) 5 13 13 17 13 14 5 16 15
Sex Male male male male male female female female Male
Date of vaccination
Time (hrs)
28 April
08.00
4M a y
08.30
8M a y
09.00
8M a y
10.30
9M a y
08.00
9M a y
08.30
9M a y
08.30
9M a y
09.30
10 May
08.30
Time of onset
symptoms{ (hrs)
9 May 11.30 12.00 13.30 09.00 11.30 19 May 14.00 10.00
Date of in-patient
hospital admission
12 May 9 May 9 May 8 May 10 May 9 May 10 May 10 May 10 May
Length of
hospitalization
(days)
1+16
(re-admission)
12 63 24 ,18 1 2 8 1 4
Vaccine type{ HBV MMR MMR MMR MMR MMR HBV varicella MMR
Swelling at
injection site1
++ +++ + + 2 +
Abscess at
injection site
++ 2 -necrosis 22 + 22
Skin rash or severe
erythema
2 local generalized generalized arm, shoulder,
left thorax
22 generalized Local
Vomiting 22 222 + 22 2
Diarrhea 22 + 2 ++ 22 2
Max. temp. (uC) 38.0 39.2 41.0 41.0 41.0 39.0 NA 39.5 38.0
InotropesI (days) 22 +(7) +(4) +(until death) 22 2 2
Respiratory support
(days)
22 +(5) +(2) +(until death) 22 2 2
Hemoglobin (g/L) 114 101 122 145 150 124 131 112 120
Leukocyte
count (10
9/L)
35,4 23,8 19 16,9 12 11 9,1 14,1 11,2
Percentage neutrophils 72 51 60 61 72 72 44 50 54
Platelet count
(10
9/L)
779 469 210 206 243 201 701 448 241
ALT level (U/l) NA NA 84 279 148 24 NA NA 19
AST level (U/l) NA NA 178 253 165 38 NA NA 32
CK level (U/l) NA NA 2,191 14,540 1,952 NA NA NA NA
Serum creatinine
(mmol/L)
NA 35 123 115 80 27 NA NA 35
Blood culture _ _ _ _ _ _ _ _ _
Pus culture MRSA** MRSA** NA MRSA** NA NA MRSA** NA NA
Antimicrobial
treatment
oxacillin,
gentamicin
vancomycin,
ciprofloxacin
vancomycin,
imipenem,
metronidazol
vancomycin
imipenem
metronidazol
oxacillin,
vancomycin,
cefotaxim,
cipofloxacin
vancomycin,
ciprofloxacin
oxacillin oxacillin,
cefotaxim
vancomycin,
ciprofloxacin
outcome recovered recovered neurological
sequelae
recovered died recovered recovered recovered recovered
{Date of vaccination unless otherwise stated.
{HBV: Hepatitis B virus. Both received Euvax B
TM; MMR: Measles, Mumps, Rubella. All received Priorix
TM; varicella: Varilrix
R.
1swelling at injection site beyond the expected after routine vaccination.
IInotropes used were dopamine, dobutamine, noradrenaline.
**MRSA: methicillin-resistant Staphylococcus aureus. NA denotes not available, a plus sign positive or present, and a minus sign negative or absent.
*Normal ranges are as follows: hemoglobin concentration, 105–135 g/L; leukocyte count, 6 to 17.5?10
9/L; platelet count, 150 to 400?10
9/L; alanine aminotransferase (ALT)
level, below 37 U/L; aspartate aminotransferase (AST) level, below 40 U/L; creatine phosphokinase (CK) below 200 U/L; serum creatinine concentration, 18–80 mmol/L;
doi:10.1371/journal.pone.0000822.t001
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e822unavailability of appropriate treatment, she remained untreated
for her MRSA carriage until 7 September 2006.
ST59 is a relatively rare lineage of S. aureus, but CA-MRSA of
this lineage has been reported in the USA [8,22]. We compared
a USA ST59 isolate HT2001-0751 with strain HCM3A, isolated
from the nose of vaccinator X. On PFGE HCM3A showed five
bands difference with HT2001-0751 (Figure 2). Microarray
analysis of strains HCM3A and HT2001-0751 showed clustering
of the core variable genes of both strains showing they belong to
the same lineage and derive from a common ancestor (Table 2).
However, there was substantial difference in MGE carriage, such
as pathogenicity islands, SCCmec, and phage (Table 2). Thus the
two strains are epidemiologically unrelated. Fully annotated
microarray data have been deposited in BmG@Sbase (accession
number: E-BUGS-45; http://bugs.sgul.ac.uk/E-BUGS-45) and
ArrayExpress (accession number: E-BUGS-45).
Figure 1. Rapidly progressive soft tissue infection after vaccination.
Severe tissue necrosis around vaccination site in Child 4, two days
following vaccination with MMR. MRSA was cultured from wound fluid.
doi:10.1371/journal.pone.0000822.g001
Figure 2. Molecular typing of MRSA isolates. Pulse-Field Gel
Electrophoresis Patterns for MRSA strains isolated from four children
vaccinated by vaccinator X (lanes 3–6 ), consecutive nasal swabs from
vaccinator X (lanes 2, 7), a nasal swab from the son of vaccinator X (lane
8 ), strain HT2001-0751 (lane 9), hospital-acquired strain CV91 (lane 1)
and strains ATCC 25923 (lane 10) and ATCC 33591 (lane 11).
doi:10.1371/journal.pone.0000822.g002
Table 2. Key virulence and resistance genes in isolates
HCM3A, HT2001 751, and MW2 as detected by microarray.
......................................................................
gene
characteristic S. aureus strain
HCM 3A Ht 2001 751 MW2
core hla hla hla
hlagACB hlgACB hlgACB
hld hld hld
clfAB clfAB clfAB
lineage ST59* ST59 ST1
cap8 cap8 cap8
sasG sasG sasG
coa M0206v coa M0206v coa M0206v
sasA insert sasA insert sasA insert
sdrDE sdrDE sdrDE
-- cna
fnbpA R2580v fnbpA R2580v fnbpA N2291v
-- lytN
agr class I agr class I agr class III
trap R1926 trap R1926 trap M1775
sarT sarT sarT
MGE**
SCCmec type V* type IV* type IV
mecA* mecA, R1, ccrA2, B2 mecA, R1, ccrA2, B2
far1 --
phage PV-luk*
# PV-luk PV-luk
seg seg seg
-- sak
-- sea
-- sek
SaPI seb* seb*-
-- sec
plasmid blaZ blaZ, I, R1 blaZ, I, R1
cadDX cadDX cadDX
arsB1,C arsR1, B1, C, arsR1, B1, C,
- bacteriocin SAR0694-5 bacteriocin SAR0695
*Confirmed with PCR and/or sequencing
**Microarray data cannot conclusively prove the location of a gene. Assignation
to a MGE is based on known location of that gene in other sequenced strains.
hla, a-haemolysin; hlgACB, c-haemolysin; hld, d-haemolysin; clf, clumping
factors; ST, sequence type using MLST; cap8, capsule type 8; sasG, accumulation
associated protein SA2285; coa M0206v, coagulase with four types described;
sasA, haemagglutinin like gene which can contain an insert; cna, collagen
binding protein; sdr, serine aspartate repeat proteins; fnbpA, fibronectin binding
protein with three types described; lytN, cell wall hydrolase; agr, accessory gene
regulator with 4 classes described; trap, target of RNAIII activating protein with
2 types described; sarT, staphylococcal accessory regulator T; MGE, mobile
genetic element; SCC, staphylococcal cassette chromosome; mec, methicillin
resistance; ccr, cassette chromosome recombinase with 3 types described; far1,
putative fusidic acid resistance; PV-luk, Panton Valentine leukocidin; seg,
enterotoxin G; sak, staphylokinase; sea, enterotoxin A; sek, enterotoxin K; seb,
enterotoxin B; sec, enterotoxin C; bla, b-lactamase; cad, cadmium resistance; ars,
arsenic resistance; bacteriocin, putative bacteriocin gene SAR0694-5; - denotes
gene not detected; #, phage unrelated to PV-luk phage in MW2.
doi:10.1371/journal.pone.0000822.t002
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We describe an outbreak of severe infections caused by CA-
MRSA acquired during routine vaccination injection. To our
knowledge this is the first CA-MRSA outbreak associated with
vaccination and linked to transmission by an asymptomatic health
care worker. The current outbreak is also different to previously
described clusters of CA-MRSA infections, as effective trans-
mission of CA-MRSA occurred during an extremely short
exposure period, i.e. during a single injection. Since the time of
injection was documented, this outbreak demonstrates the short
incubation period of severe disease caused by CA-MRSA. It also
demonstrates that a single strain of CA-MRSA is capable of
causing a spectrum of disease in otherwise healthy children,
ranging from fatal toxic shock syndrome, necrotizing soft tissue
infection, to abscesses at the injection site.
While bacterial infection associated with vaccination is occa-
sionally reported, severe infections and deaths are uncommon.
One case of toxic shock syndrome caused by Streptococcus pyogenes
associated with vaccination by an asymptomatic colonized surgeon
has been reported [23]. A review of AEFI in the US found only
250 (0.2%) reports of bacterial infection and 318 (0.2%) injection
site abscesses among 128,717 adverse events reported during
1999–2001 when an estimated .1.9 billion vaccinations were
administered [24]. The incidence of such events is likely to be
variable in different settings and related to infection control
practices as well as reporting practices. Severe bacterial infections,
including TSS and soft tissue infections, have been linked with
administration of multi-dose lyophilized vaccines [25]. However,
in this outbreak the infections resulted from administration of
single-dose lyophilized or two-dose liquid vaccines.
The results of the investigations suggested all children were
infected by a common source. At the start of the outbreak a single
MMR vaccine product was considered a potential source of
infection. However the subsequent testing of that vaccine and the
outcome of the investigation ruled out contamination. We did not
study MRSA carriage in the affected children. However, the
negative swab samples from the children’s mothers suggest the
circulation of strain HCM3A in different households, followed by
autologous infection during vaccination, was unlikely. Cases of
sepsis syndrome and rapidly progressive and fatal pneumonia
caused by PVL-positive CA-MRSA, have been described in
children worldwide [26] [4,27,28]. Child 6, 7 and 9 presented with
relatively mild illness without localized symptoms. Unfortunately,
additional diagnostic specimens were not obtained which pre-
cluded exclusion of other etiologies of AEFI.
Vaccinator X, with 17 years of prior experience as a vaccinator,
was found to be a healthy transient carrier of CA-MRSA strain
HCM3A who transmitted the strain during a two week period
in which she performed vaccinations. None of her household
members carried the same strain yet the transmission to the
affected children occurred very efficiently during an extremely
short period of contact. The vaccinator reported symptoms of
a common cold during this period and the presence of an upper
respiratory viral infection may have resulted in increased shedding
of the carriage strain from nose and throat [29].
Insufficient hand hygiene during vaccine handling may have
further contributed to the transmission of CA- MRSA. Current
WHO recommendations do not require swabbing the injection
site with isopropyl alcohol prior to vaccination unless the skin is
visibly soiled or dirty [30]. However, the vaccinator reported that
she routinely did this. Healthy carriers can transmit S. aureus by
shedding the bacteria from the nose or other carriage sites into the
environment and the air [31]. While determination of the precise
route of transmission is impossible, we hypothesize that shedding
of CA-MRSA, possibly increased due to the presence of
a concurrent upper respiratory tract infection, may have resulted
in contamination of the vaccine or the needle during vaccine
preparation, or of the skin surface after disinfection. Our
investigation highlights the potential risks of transmission of CA-
MRSA and the importance of appropriate infection control
measures, even during a short routine procedure such as injection
in an out-patient setting. This investigation, for which all the work,
with the exception of the microarray data, was undertaken in Ho
Chi Minh City, highlights the benefits of having rapidly available
multidisciplinary expertise at the site, capable of conducting
detailed clinical, epidemiological, and molecular analysis of the
outbreak and the causative microorganism.
Strain HCM3A showed all the characteristics of a CA-MRSA
strain with low level oxacillin resistance that can easily be missed on
testing, susceptibility to most other agents tested, and the presence of
SCCmec type V. It contained several virulence factors that are
associated with severe infections caused by S. aureus, including PV-luk
and seb, on MGE [32,33]. HCM3A belonged to the lineage ST59,
which has also been described as causing CA-MRSA outbreaks in
the USA, and strains of this lineage have been identified in the
Netherlands, Singapore and Taiwan [10,34](www.mlst.net) suggest-
ing this lineage is spreading around the world. However, HCM3A
carries many variant MGE compared to the USA strain and
therefore is likely to be epidemiologically unrelated. It is likely that
HCM3A evolved independently from methicillin-sensitive ST59 S.
aureus, which acquired SCCmec and a range of virulence MGE. This
confirms earlier observations that strains belonging to the same
lineage as determined by MLST, can evolve significantly from each
other [7,35]. The spectrum of disease caused by the single strain
HCM3A was varied and likely to be influenced by host factors.
Similarly, other well characterised CA-MRSA strains, including the
two from which the whole genome sequence has been determined,
have caused a spectrum of disease. Strain MW2 (USA400, ST1)
[36], which is included in our microarray, was the prototype CA-
MRSA while strain USA300 (ST8) [37] has reached epidemic
proportions in the United States [6]. Each belong to different
lineages, yet can cause a similar range of diseases, emphasizing the
key role of host factors in determining clinical presentation.
This outbreak is the first report of severe infections due to CA-
MRSA in Viet Nam. It had a negative impact on vaccine uptake
and resulted in a temporary nationwide suspension of MMR
vaccination. The results of the investigation suggest that insufficient
attention to hand hygiene may have led to transmission of CA-
MRSA. Given the increasing prevalence of CA-MRSA worldwide,
adherence to effective infection control strategies is paramount to
prevent transmission of CA-MRSA and further outbreaks.
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